Assistant Professor, Harvard Medical School, Boston MA Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Boston MA Associate Member, Broad Institute
The chromatin regulators CBP and p300 maintain gene expression programs through lysine acetylation of chromatin and transcriptional regulators and by scaffolding functions mediated by several protein-protein interaction domains. We have developed a chemical degrader of p300/CBP, dCBP-1, using in silico modeling and cellular activity assays including capillary-based immunodetection assays (ProteinSimple, WES). We have found that dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drive MYC oncogene expression. As an efficient degrader of this unique class of chromatin regulators, dCBP-1 will be a useful tool for understanding p300/CBP activity at enhancers in both normal and diseased cells.
Webinars will be available for unlimited on-demand viewing after live event.
Parkinson’s disease (PD) remains one of the most challenging neurodegenerative disorders to diagnose and monitor. Conventional clinical assessments and imaging often miss the early mol...
Immunotherapy has transformed cancer treatment, but persistent challenges, such as T cell exhaustion, limited persistence, and variability in response, continue to impact therapeutic success...
Join us for an insightful webinar to discuss a holistic approach to testing for TB in a clinical setting. Tuberculosis remains a global health challenge and accurate, timely diagnosis is cri...
Personalized medicine promises to significantly improve patient outcomes, but achieving this requires a deep understanding of human health and disease mechanisms at the molecular level. The...
CAR-T translational research demands precise, reproducible, and scalable flow cytometry workflows. Manual centrifugation and antibody preparation steps remain major sources of variability an...
Lipid nanoparticles (LNPs) have become the gold standard in non-viral gene delivery technologies, exemplified by the approval of the LNP messenger RNA (mRNA) vaccines against SARS-CoV-2. Sin...
Loading Comments...
Please update your information
Certificate of Participation
Thank you for choosing Labroots. Please note that a Certificate of Participation does NOT count towards Continuing Education Credits.